Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Regeneron Pharmaceuticals Inc. buy PapaSmurf

Start price
€268.00
19.10.19 / 50%
Target price
-
19.12.19
Performance (%)
25.13%
End price
€335.35
19.12.19
Summary
This prediction ended on 19.12.19 with a price of €335.35. The BUY prediction by PapaSmurf finished with a performance of 25.13%. PapaSmurf has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Performance without dividends (%)
Name 1w 1m 1y 3y
Regeneron Pharmaceuticals Inc. -0.280% -0.280% 16.787% 120.312%
iShares Core DAX® 1.883% 5.122% 21.667% 22.437%
iShares Nasdaq 100 0.125% 2.574% 45.951% 55.507%
iShares Nikkei 225® -0.201% 4.341% 28.806% 9.945%
iShares S&P 500 0.728% 4.141% 34.630% 50.086%

Comments by PapaSmurf for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren

Buy Regeneron Pharmaceuticals Inc.

Prediction Buy
Perf. (%) 25.13%
Target price
Change
Ends at 19.12.19

Buy beendet